Develops and manufactures generic and specialty pharmaceuticals. Offers a wide range of dosage forms including tablets, injectables, and creams. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The gap is $13.8B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 30.6× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 58% of them.
Analysts' average target sits 21% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 4 years, sales grew only 2% a year on average — the report card’s higher growth grade leans on profit power instead.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 24/100.
On our five-subject report card, TEVA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TEVA is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (58/100) says the stock isn’t cheap.